New Platform Set To Accelerate Early-Stage Targeted Protein Degradation ProgrammesVicky Coghlan2024-11-28T14:07:30+00:00March 7th, 2023|Article, BioCity Nottingham, News|
Pioneer Group Announce Lead Investment In Selentus ScienceVicky Coghlan2024-11-28T14:49:26+00:00February 7th, 2023|BioCity Nottingham, Investment, News|
Pioneer Group And Ignite To Welcome 75 Young Women To BioCity Nottingham To Learn About Careers In STEMHannah Andrews2024-11-21T10:41:59+00:00October 1st, 2022|BioCity Nottingham|
Nottingham Marketing Pro Joins V FormationGemma Cann2024-11-28T14:50:18+00:00July 29th, 2022|BioCity Nottingham, News|
Platelet Services Doubles Lab Footprint At BioCity NottinghamGemma Cann2024-11-28T14:50:59+00:00July 4th, 2022|BioCity Nottingham, News|
Upperton Pharma Solutions Announces £15m Investment In New FacilitiesGemma Cann2024-11-28T14:54:01+00:00May 23rd, 2022|BioCity Nottingham, News|
Reach Separations Marks 10th Birthday Milestone With Further Expansion Into EuropeGemma Cann2024-11-28T14:54:18+00:00May 17th, 2022|BioCity Nottingham, News|
Sygnature Discovery Acquires Peak ProteinsGemma Cann2022-06-30T11:28:07+01:00April 28th, 2022|BioCity Nottingham, News|
OMass Therapeutics Raises $100 million To Progress Drug Pipeline In Immunology And Rare DiseasesGemma Cann2024-11-28T14:55:20+00:00April 28th, 2022|BioCity Nottingham, News|
Milestone Anniversary ‘A Proud Landmark’ For V Formation’s DirectorsGemma Cann2024-11-28T14:55:36+00:00April 26th, 2022|BioCity Nottingham, News|
